Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- QURE
- Price
- 16.90
- Stock movement down
- -0.37 (-2.14%)
- Company name
- Uniqure NV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 823.76M
- Ent værdi
- 1.16B
- Pris/omsætning
- 28.82
- Pris/bog
- 14.76
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 22.59%
- 1 års afkast
- 211.23%
- 3 års afkast
- 4.83%
- 5 års afkast
- -23.09%
- 10 års afkast
- -5.85%
Senest opdateret: 2025-06-10
iO Charts is a Seeking Alpha partner
uniQure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs AMT-130’s BLA. See more on QURE here.
28. maj 2025
iO Charts is a Seeking Alpha partner
UDBYTTE
QURE betaler ikke udbytte
uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsChiara Russo - Senior Director, Investor RelationsMatt...
10. maj 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 28.82 |
| Pris til egenkapital | 14.76 |
| EV i forhold til salg | 40.65 |
uniQure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn why QURE stock is a buy.
8. maj 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 48.74M |
| EPS (TTM) | -4.92 |
| FCF pr. aktie (TTM) | -3.79 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 28.59M |
| Bruttofortjeneste (TTM) | -3.25M |
| Driftsindkomst (TTM) | -204.74M |
| Nettoindkomst (TTM) | -239.50M |
| EPS (TTM) | -4.92 |
| EPS (1 år frem) | -3.12 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | -11.39% |
| Driftsmargin (TTM) | -716.18% |
| Fortjenstmargin (TTM) | -837.80% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 251.63M |
| Nettotilgodehavender | 5.32M |
| Omsætningsaktiver i alt | 464.14M |
| Goodwill | 24.08M |
| Immaterielle aktiver | 76.61M |
| Ejendomme, anlæg og udstyr | 71.20M |
| Sum aktiver | 645.81M |
| Kreditor | 5.44M |
| Kortfristet/nuværende langsigtet gæld | 67.60M |
| Summen af kortfristede forpligtelser | 71.27M |
| Sum gæld | 589.99M |
| Aktionærernes egenkapital | 55.82M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -179.05M |
| Investeringsudgifter (TTM) | 5.40M |
| Fri pengestrøm (TTM) | -184.45M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -429.05% |
| Afkast af aktiver | -37.09% |
| Afkast af investeret kapital | -207.31% |
| Kontant afkast af investeret kapital | -159.66% |
uniQure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.
21. april 2025
iO Charts is a Seeking Alpha partner
uniQure's AMT-130 gene therapy for Huntington’s Disease shows promising trial data. Check out my recommendation for QURE stock.
21. april 2025
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 17.53 |
| Daglig høj | 17.58 |
| Daglig lav | 16.53 |
| Daglig volumen | 988K |
| Højeste gennem alle tider | 82.19 |
| 1 års analytiker estimat | 29.64 |
| Beta | 0.90 |
| EPS (TTM) | -4.92 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 18 Jun 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| QURE | S&P500 | |
| Nuværende prisfald fra top notering | -79.44% | -2.16% |
| Højeste prisfald | -95.40% | -56.47% |
| Højeste efterår dato | 8 Jul 2024 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -55.38% | -11.05% |
| Gennemsnitlig tid til nyt højdepunkt | 58 days | 12 days |
| Maks. tid til nyt højdepunkt | 1500 days | 1805 days |
uniQure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing therapies for ALS & Fabry, and with FDA talks in 2025.
19. april 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
823.76M
Markedsværdi kategori
Small-cap
Beskrivelse
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Personale
480
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Matthew C. Kapusta
Land
USA
By
Amsterdam
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
uniQure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting measures and analyst support.
26. februar 2025
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Seeking AlphaPressemeddelelser
uniQure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy.
20. februar 2025
uniQure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.
10. december 2024
uniQure's valuation appears slightly high relative to peers, with limited upside potential. Click here to learn why QURE stock is a Hold.
21. oktober 2024
iO Charts is a Seeking Alpha partnerNæste side